CNBX-RCK

CNBX-RCK appears to be an **investigational cannabinoid-derived cannabis chemovar or extract candidate** associated with a collaboration between CNBX Pharmaceuticals and RCK Medical Cannabis. Publicly available information identifies it only as an RCK-derived cannabis strain or extract tested by Cannabics in preclinical high-throughput screening, where an extract of the CNBX-RCK cannabis plant 802-2 reportedly showed anti-tumor activity against gastric adenocarcinoma cells. The precise active ingredients, cannabinoid composition, formulation, route of administration, and validated molecular mechanism have not been publicly disclosed, so it is best characterized as an early preclinical cannabinoid mixture intended as a potential source of future oncology-focused active pharmaceutical ingredients rather than a defined approved drug.

Other names

CNBX-RCK cannabis plant 802-2CNBX-RCK cannabis extract